The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma
Open accessAbstract
Intra-arterial injection of radioactive Lipiodol has shown promising results in patients with hepatocellular carcinoma (HCC) and portal obstruction. The aim of this prospective, randomized trial was to compare the efficacy and tolerance of 131 I-labeled Lipiodol and chemoembolization for the treatment of patients with HCC. From September 1990 to September 1993, 142 patients (135 men, 7 women; age: 65 ± 6.6 years) were randomly assigned to treatment groups and given either intra-arterial injections of 131 I-labeled Lipiodol (60 mCi; 2.2 GBq) (n = 73) or chemoembolization (70 mg cisplatin) (n = 69). Subsequent injections were given at 2, 5, 8, 12, and 18 months. Tumor response was assessed on the basis of tumor size and serum α-fetoprotein levels. Patient tolerance was assessed clinically and angiographically. Survival rate was the main end-point. A total of 129 patients (65 in the 131 I-labeled Lipiodol group and 64 in the chemoembolization group) were available for analysis; 13 were excluded, mainly because of portal vein thrombosis. The two groups were comparable. Actuarial survival curves were not significantly different between the two groups. Overall survival rates at 6 months, 1, 2, 3, and 4 years were 69%, 38%, 22%, 14%, and 10%, and 66%, 42%, 22%, 3%, and 0% in the 131 I-labeled Lipiodol and chemoembolization groups, respectively. Reduction in tumor size was similar for the two groups, with complete response in 1 and 0 patients and partial response in 15 and 16 patients in the 131 I-labeled Lipiodol and chemoembolization groups, respectively. Tolerance was significantly better in the 131 I- labeled Lipiodol group both clinically (3 severe side effects vs. 29 in the chemoembolization group; P < .001) and angiographically (1 arterial thrombosis vs. 10 in the chemoembolization group; P < .01). In terms of patient survival and tumor response, radioactive 131 I-labeled Lipiodol and chemoembolization were equally effective in the treatment of HCC, but tolerance to 131 I-labeled Lipiodol was significantly better.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Lammer, J., Malagari, K., Vogl, T., Pilleul, F., Denys, A., Watkinson, A., Pitton, M., Sergent, G., Pfammatter, T., Terraz, S., et al. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-009-9711-7 · Cited by 1,557
Hepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Cammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update
Vivarelli, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i42.7316 · Cited by 799
Marelli, L., Stigliano, R., Triantos, C., Senzolo, M., Cholongitas, E., Davies, N., Tibballs, J., Meyer, T., Patch, D. W., & Burroughs, A. K. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-006-0062-3 · Cited by 791
Chemoembolization for hepatocellular carcinoma
Bruix, J., Sala, M., & Llovet, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.032 · Cited by 569
Lau, W., Leung, T., Ho, S., Chan, M., Machin, D., Lau, J., Chan, A., Yeo, W., Mok, T., Yu, S., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06475-7 · Cited by 409
Hepatocellular Carcinoma: The Need for Progress
Thomas, M. B., & Zhu, A. X. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.196 · Cited by 406
Salem, R., Lewandowski, R. J., Atassi, B., Gordon, S. C., Gates, V. L., Barakat, O., Sergie, Z., Wong, C.-Y. O., & Thurston, K. G. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000184594.01661.81 · Cited by 404
Dawson, L. A., McGinn, C. J., Normolle, D., Ten Haken, R. K., Walker, S., Ensminger, W., & Lawrence, T. S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2210 · Cited by 395
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Hepatocellular Carcinoma-Cause, Treatment and Metastasis
Tang, Z.-Y. (2001) · World Journal of Gastroenterology · doi:10.3748/wjg.v7.i4.445 · Cited by 375
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
LOPEZ, P. M., VILLANUEVA, A., & LLOVET, J. M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02932.x · Cited by 344
Radioembolization for hepatocellular carcinoma
Sangro, B., Iñarrairaegui, M., & Bilbao, J. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.012 · Cited by 315
Poon, R. T. P., Tso, W. K., Pang, R. W. C., Ng, K. K. C., Woo, R., Tai, K. S., & Fan, S. T. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.04.021 · Cited by 294
Treatment of Hepatocellular Carcinoma
Bruix, J. (1997) · Hepatology · doi:10.1002/hep.510250201 · Cited by 277
Chemoembolization of Hepatocellular Carcinoma
Ramsey, D. E., Kernagis, L. Y., Soulen, M. C., & Geschwind, J.-F. H. (2002) · Journal of Vascular and Interventional Radiology · doi:10.1016/s1051-0443(07)61789-8 · Cited by 271
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Metadata
- Authors
- Raoul, J., Guyader, D., Bretagne, J., Heautot, J., Duvauferrier, R., Bourguet, P., Bekhechi, D., Deugnier, Y. M., & Gosselin, M.
- Venue
- Hepatology
- Published
- 1997-11
- Volume
- 26
- Issue
- 5
- Pages
- 1156-1161
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2009038056
- Cited by
- 286
- References
- 1
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.